---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-080277"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:30:04.066683+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma inks collaboration with Boehringer Ingelheim for B cell depletion; $12M upfront

## Summary
- Upfront payment of $12M; eligible for up to $345M in success-based research, development, and commercial milestones.
- BI gets exclusive worldwide license to develop and commercialize CUE-501 and other B cell depletion molecules.
- Cue prohibited from developing or commercializing any B cell depletion molecules during the 4-year research term.
- BI will pay research support during research term; royalties on net sales subject to standard reductions.
- Amendment with Einstein College of Medicine allows sublicense to BI and adjusts upstream payment obligations.

## SEC filing metadata
- accession: 0001193125-25-080277
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312525080277/0001193125-25-080277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312525080277/d894534d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-080277
- JSON: https://secwatch.observer/filing/0001193125-25-080277.json
- Plain text: https://secwatch.observer/filing/0001193125-25-080277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.